Analysis of polypeptide expression in benign and malignant human breast lesions. 1997

B Franzén, and S Linder, and A A Alaiya, and E Eriksson, and K Fujioka, and A C Bergman, and H Jörnvall, and G Auer
Unit of Cell and Molecular Analysis, Karolinska Institute and Hospital, Stockholm, Sweden.

Results of two-dimensional electrophoresis (2-DE) analyses of human breast carcinoma are described. Tumor cells were extracted and purified from breast carcinomas with different proliferative indeces and degrees of genomic stability. Cells purified from fibroadenoma tissue served as controls for benign cells. The following results were observed: (i) Analysis of samples from different areas of the same tumor showed a high degree of similarity in the pattern of polypeptide expression. Similarly, analysis of two tumors and their metastases revealed similar 2-DE profiles. (ii) In contrast, large variations were observed between different lesions with comparable histological characteristics. Larger differences in polypeptide expression were observed between potentially highly malignant carcinomas compared to comparisons of less malignant lesions. These differences were in the same order of magnitude as those observed comparing a breast carcinoma to a lung carcinoma. (iii) The levels of all cytokeratin forms resolved (CK7, CK8, CK15, and CK18) were significantly lower in carcinomas compared to fibroadenomas. (iv) The levels of high molecular weight tropomyosins (1-3) were lower in carcinomas compared to fibroadenomas. The expression of tropomyosin-1 was found to be 1.7-fold higher in primary tumors with metastatic spread to axillar lymph nodes compared to primary tumors with no evidence of metastasis (p < 0.05). (v) The expression of proliferating cell nuclear antigen (PCNA) and some members of the stress protein family (pHSP60, HSP90, and calreticulin) were higher in carcinomas. We conclude that malignant progression of breast carcinomas results in large heterogeneity in polypeptide expression between different tumors, but that some common themes such as decreased expression of cytokeratin and tropomyosin polypeptides can be discerned.

UI MeSH Term Description Entries
D007633 Keratins A class of fibrous proteins or scleroproteins that represents the principal constituent of EPIDERMIS; HAIR; NAILS; horny tissues, and the organic matrix of tooth ENAMEL. Two major conformational groups have been characterized, alpha-keratin, whose peptide backbone forms a coiled-coil alpha helical structure consisting of TYPE I KERATIN and a TYPE II KERATIN, and beta-keratin, whose backbone forms a zigzag or pleated sheet structure. alpha-Keratins have been classified into at least 20 subtypes. In addition multiple isoforms of subtypes have been found which may be due to GENE DUPLICATION. Cytokeratin,Keratin Associated Protein,Keratin,Keratin-Associated Proteins,alpha-Keratin,Associated Protein, Keratin,Keratin Associated Proteins,Protein, Keratin Associated,alpha Keratin
D009362 Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. Metastase,Metastasis,Metastases, Neoplasm,Metastasis, Neoplasm,Neoplasm Metastases,Metastases
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014335 Tropomyosin A protein found in the thin filaments of muscle fibers. It inhibits contraction of the muscle unless its position is modified by TROPONIN. Paramyosin,Miniparamyosin,Paratropomyosin,Tropomyosin Mg,alpha-Tropomyosin,beta-Tropomyosin,gamma-Tropomyosin,Mg, Tropomyosin,alpha Tropomyosin,beta Tropomyosin,gamma Tropomyosin

Related Publications

B Franzén, and S Linder, and A A Alaiya, and E Eriksson, and K Fujioka, and A C Bergman, and H Jörnvall, and G Auer
March 1989, Oncogene,
B Franzén, and S Linder, and A A Alaiya, and E Eriksson, and K Fujioka, and A C Bergman, and H Jörnvall, and G Auer
December 2016, Investigacion clinica,
B Franzén, and S Linder, and A A Alaiya, and E Eriksson, and K Fujioka, and A C Bergman, and H Jörnvall, and G Auer
April 2004, Histology and histopathology,
B Franzén, and S Linder, and A A Alaiya, and E Eriksson, and K Fujioka, and A C Bergman, and H Jörnvall, and G Auer
October 1997, International journal of cancer,
B Franzén, and S Linder, and A A Alaiya, and E Eriksson, and K Fujioka, and A C Bergman, and H Jörnvall, and G Auer
June 2001, La Radiologia medica,
B Franzén, and S Linder, and A A Alaiya, and E Eriksson, and K Fujioka, and A C Bergman, and H Jörnvall, and G Auer
January 1998, Acta cytologica,
B Franzén, and S Linder, and A A Alaiya, and E Eriksson, and K Fujioka, and A C Bergman, and H Jörnvall, and G Auer
June 1987, British journal of cancer,
B Franzén, and S Linder, and A A Alaiya, and E Eriksson, and K Fujioka, and A C Bergman, and H Jörnvall, and G Auer
January 1983, Ultrasound in medicine & biology,
B Franzén, and S Linder, and A A Alaiya, and E Eriksson, and K Fujioka, and A C Bergman, and H Jörnvall, and G Auer
January 2010, Indian journal of pathology & microbiology,
B Franzén, and S Linder, and A A Alaiya, and E Eriksson, and K Fujioka, and A C Bergman, and H Jörnvall, and G Auer
October 2007, World journal of surgical oncology,
Copied contents to your clipboard!